These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 25982114)

  • 1. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
    Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
    Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
    Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
    Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
    Puissant A; Frumm SM; Alexe G; Bassil CF; Qi J; Chanthery YH; Nekritz EA; Zeid R; Gustafson WC; Greninger P; Garnett MJ; McDermott U; Benes CH; Kung AL; Weiss WA; Bradner JE; Stegmaier K
    Cancer Discov; 2013 Mar; 3(3):308-23. PubMed ID: 23430699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromodomain-containing protein 4 regulates a cascade of lipid-accumulation-related genes at the transcriptional level in the 3T3-L1 white adipocyte-like cell line.
    Mochizuki K; Yamada M; Inoue T; Hariya N; Kubota T; Goda T
    Eur J Pharmacol; 2020 Sep; 883():173351. PubMed ID: 32650006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomain and extraterminal inhibitors block the Epstein-Barr virus lytic cycle at two distinct steps.
    Keck KM; Moquin SA; He A; Fernandez SG; Somberg JJ; Liu SM; Martinez DM; Miranda JL
    J Biol Chem; 2017 Aug; 292(32):13284-13295. PubMed ID: 28588024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain and extraterminal (BET) protein inhibition suppresses human T cell leukemia virus 1 (HTLV-1) Tax protein-mediated tumorigenesis by inhibiting nuclear factor κB (NF-κB) signaling.
    Wu X; Qi J; Bradner JE; Xiao G; Chen LF
    J Biol Chem; 2013 Dec; 288(50):36094-105. PubMed ID: 24189064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition.
    Rathert P; Roth M; Neumann T; Muerdter F; Roe JS; Muhar M; Deswal S; Cerny-Reiterer S; Peter B; Jude J; Hoffmann T; Boryń ŁM; Axelsson E; Schweifer N; Tontsch-Grunt U; Dow LE; Gianni D; Pearson M; Valent P; Stark A; Kraut N; Vakoc CR; Zuber J
    Nature; 2015 Sep; 525(7570):543-547. PubMed ID: 26367798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperation between PU.1 and CAAT/enhancer-binding protein beta is necessary to induce the expression of the MD-2 gene.
    Tissières P; Araud T; Ochoda A; Drifte G; Dunn-Siegrist I; Pugin J
    J Biol Chem; 2009 Sep; 284(39):26261-72. PubMed ID: 19632992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Forced FOG1 expression in erythroleukemia cells: Induction of erythroid genes and repression of myelo-lymphoid transcription factor PU.1.
    Fujiwara T; Sasaki K; Saito K; Hatta S; Ichikawa S; Kobayashi M; Okitsu Y; Fukuhara N; Onishi Y; Harigae H
    Biochem Biophys Res Commun; 2017 Apr; 485(2):380-387. PubMed ID: 28216155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
    Shu S; Lin CY; He HH; Witwicki RM; Tabassum DP; Roberts JM; Janiszewska M; Huh SJ; Liang Y; Ryan J; Doherty E; Mohammed H; Guo H; Stover DG; Ekram MB; Brown J; D'Santos C; Krop IE; Dillon D; McKeown M; Ott C; Qi J; Ni M; Rao PK; Duarte M; Wu SY; Chiang CM; Anders L; Young RA; Winer E; Letai A; Barry WT; Carroll JS; Long H; Brown M; Liu XS; Meyer CA; Bradner JE; Polyak K
    Nature; 2016 Jan; 529(7586):413-417. PubMed ID: 26735014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.
    Martens JH; Mandoli A; Simmer F; Wierenga BJ; Saeed S; Singh AA; Altucci L; Vellenga E; Stunnenberg HG
    Blood; 2012 Nov; 120(19):4038-48. PubMed ID: 22983443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
    Blee AM; Liu S; Wang L; Huang H
    Oncotarget; 2016 Jun; 7(25):38319-38332. PubMed ID: 27223260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
    Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
    Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
    Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
    Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.
    Chen HS; De Leo A; Wang Z; Kerekovic A; Hills R; Lieberman PM
    PLoS Pathog; 2017 Jan; 13(1):e1006100. PubMed ID: 28107481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements.
    Bhagwat AS; Roe JS; Mok BYL; Hohmann AF; Shi J; Vakoc CR
    Cell Rep; 2016 Apr; 15(3):519-530. PubMed ID: 27068464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.